When was Chrono Therapeutics founded?

Chrono Therapeutics was founded in 2004 and raised its 1st funding round 8 years after it was founded.

Where is Chrono Therapeutics located?

Chrono Therapeutics is headquartered in Waltham, United States.

Who is the current CEO of Chrono Therapeutics?

Alan Levy of Chrono Therapeutics.

Is Chrono Therapeutics a funded company?

Chrono Therapeutics is a funded company, having raised a total of $82.2M across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 21, 2012.

When was the latest funding round of Chrono Therapeutics?

Chrono Therapeutics' latest funding was a $***** Series B round on Sep 28, 2016, with participation from 1 investor. Its primary sector is Drug Delivery. In United States, the Drug Delivery sector has seen $196M in funding in 2026 to date.

Where does Chrono Therapeutics rank among its competitors?

Chrono Therapeutics ranks 50th amongst 183 active competitors, of which 55 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was CeQur, which secured $100M in Jun, 2026.

Who are the top competitors of Chrono Therapeutics?

Chrono Therapeutics' top competitors include Omada, Welldoc and Wellthy Therapeutics. Among them, CeQur secured the most recent funding round in June, 2026.

Chrono Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Chrono Therapeutics is a deadpooled company based in Waltham (United States), founded in 2004 by Guy DiPierro. It operates as an A transdermal nicotine replacement therapy for smoking cessation.. Chrono Therapeutics has raised $82.2M in funding from investors like Canaan, Kaiser Permanente Ventures and 5AM Ventures. The company has 183 active competitors, including 55 funded and 20 that have exited. Its top competitors include companies like Omada, Welldoc and Wellthy Therapeutics.

Company Details

Chrono Therapeutics has developed a device with programmable passive transdermal drug delivery (TDD) system. Their first product, StopSmart, is a wearable wrist, arm, or as an adhesive patch, that helps a user in smoking cessation. The wearable is attached to user's body and is controlled by a smartphone app where the user can set up a time to start administering nicotine. Based on past start times devices releases nicotine in a controlled amount at different interval of time rather than continuously, throughout the day over a 10-week period. The drug delivery system is coupled with real-time behavioral support therapy via the connected smartphone app. The platform could also be used for delivery of various other drugs for conditions including Parkinson’s, asthma, and ADHD. Chrono is planning to apply for approval in 2016 and launch device in 2017.

Website: chronothera.com
Social

Key Metrics

Founded Year

2004

Location

Waltham, United States

Stage

Deadpooled

Total Funding

$82.2M in 8 rounds

Latest Funding Round

Series B, Sep 28, 2016, $*****

Investors

Canaan & 16 more

Ranked

50^th among 183 active competitors

Similar Companies

Omada & 245 more

View Chrono Therapeutics' full profile

Chrono Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Chrono Therapeutics Inc. CIN: 02-0680326 , United States, Active	Feb 17, 2003	-	-	-

Chrono Therapeutics has raised a total funding of $82.2M over 8 rounds. Its first funding round was on Sep 21, 2012. Its latest funding round was a Series B round on Sep 28, 2016 for $*****. 1 investor participated in its latest round. Chrono Therapeutics has 17 institutional investors.

Here is the list of recent funding rounds of Chrono Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 28, 2016	5738791	Series B	7926881	5716591	4232789	8028335
Sep 09, 2016	7641770	Series B	2782112	7427312	1497915	Endeavour Vision & 11 more
Aug 25, 2015	2513441	Grant (prize money)	3688071	3078833	6917390	National Cancer Institute

Access funding benchmarks and valuations. Sign up today!

View details of Chrono Therapeutics's funding rounds and investors

The founders of Chrono Therapeutics is Guy DiPierro.

Here are the details of Chrono Therapeutics' key team members:

Guy DiPierro: Former Founder of Chrono Therapeutics.
Alan Levy: CEO of Chrono Therapeutics.

View details of Chrono Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Chrono Therapeutics include Omada, Welldoc and Wellthy Therapeutics. Here is the list of Top 10 competitors of Chrono Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Omada 2011, San Francisco (United States), Public	Provider of virtual care programs to manage chronic diseases	$450M	Fidelity Investments, TriplePoint Capital ... & 44 others	80/100
2nd	Welldoc 2005, Columbia (United States), Series B	Provider of mobile health products for chronic disease management	$82.1M	Windham Venture Partners, Merck Global Health Innovation Fund ... & 13 others	71/100
3rd	Wellthy Therapeutics 2015, Mumbai (India), Acquired	Provider of a health monitoring app for chronic health patients and providers	$8.91M	Bayer, Manipal Group & 32 others	69/100
4th	SidekickHealth 2013, Palo Alto (United States), Series B	Provider of gamified social health and wellness solution	$76.5M	Novator Partners, Wellington Partners Venture Capital ... & 7 others	68/100
5th	Vaxxas 2010, Brisbane (Australia), Series D	Developer of a needle-free patch technology for vaccine delivery applications	$91.2M	One Ventures, UniQuest & 12 others	65/100
6th	Pivot 2015, San Carlos (United States), Series B	Provider of application for smoking de-addiction	$37.5M	Johnson & Johnson Innovation – JJDC, Khosla Ventures ... & 6 others	62/100
7th	Fitterfly 2016, Navi Mumbai (India), Acquired	Digital therapeutics platform focused on managing and preventing metabolic health conditions	$18.9M	Fireside Ventures, 100Unicorns & 42 others	61/100
8th	scPharmaceuticals 2013, Lexington (United States), Acquired	Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure	$78.7M	Orbimed, Sun Pharma & 4 others	60/100
9th	CeQur 2008, Horw (Switzerland), Series E	Developer of wearable insulin delivery patch	$492M	Endeavour Vision, Schroders & 7 others	58/100
10th	BioSapien 2018, New York City (United States), Seed	Developer of 3D-printed drug delivery platforms for targeted pharmaceutical agents	$10.6M	JPIN, Global Ventures & 13 others	58/100
50th	Chrono Therapeutics 2004, Waltham (United States), Deadpooled	A transdermal nicotine replacement therapy for smoking cessation.	$82.2M	Mayo Clinic Business Accelerator, Endeavour Vision ... & 15 others	35/100